Table 2. Cox-regression analysis for composite end point/progression.
| Determinant | Univariable (HR, 95% CI (P)) | Multivariable (HR, 95% CI) |
|---|---|---|
| Age | 0.94 (0.88–0.99 (P=0.03)) | 0.96 (0.90–1.01 (P=0.13)) |
| ADT | 2.15 (1.06–4.37 (P=0.04)) | 1.69 (0.80–3.61 (P=0.17)) |
| PSA | 1.00 (0.97–1.04 (P=0.95)) | — |
| PSA nadir | ||
| >0.5 versus <0.5 | 2.63 (1.22–5.69 (P=0.01)) | 2.61 (1.19–5.73 (P=0.02)) |
| No nadir versus <0.5 | 35.11 (10.64–115.81 (P<0.0001)) | 28 (8.29–94.53 (P<0.0001)) |
| NCCN risk group (high versus intermediate) | 1.22 (0.62–2.40 (P=0.57)) | — |
Abbreviations: ADT, androgen-deprivation therapy; CI, confidence interval; HR, hazard ratio; NCCN, National Comprehensive Cancer Network.